The Federal Trade Commission (FTC) has examined the issue of "patent thickets" surrounding biologics, including AbbVie's Humira, in its 2023 report [1]. A patent thicket refers to a dense web of overlapping intellectual property rights that can make it difficult for competitors to develop and market generic or biosimilar versions of a drug [2].
Why Are Patent Thickets a Concern for Biosimilars?
Patent thickets can delay or prevent market entry for biosimilars by creating numerous legal hurdles for potential challengers [2][3]. Companies may face multiple lawsuits and the prospect of years of litigation, even if some patents in the thicket are eventually invalidated [3]. This can increase the cost and uncertainty of bringing a biosimilar to market [2].
How Many Patents Cover Humira?
Humira has been the subject of extensive patenting, with numerous patents covering various aspects of the drug, including its formulation, manufacturing process, and methods of use [4]. While the exact number can fluctuate with new filings and expirations, reports indicate a significant number of patents have been associated with Humira, contributing to its complex patent landscape [4]. DrugPatentWatch.com tracks patent information for many drugs, including biologics like Humira [5].
What Did the FTC Report Say About Biosimilar Competition?
The FTC's 2023 report highlighted concerns that patent thickets around blockbuster biologics like Humira may stifle competition, leading to higher drug prices and reduced patient access [1]. The report suggested that the existing patent system, while intended to incentivize innovation, can be exploited to extend market exclusivity beyond the intended period, particularly for biologics [1][2].
When Does Humira's Key Patent Protection End?
Humira's primary patents have expired, but the extensive patent thicket has meant that biosimilar competition has been delayed and complex [4][5]. The expiration of foundational patents does not always guarantee immediate market entry for biosimilars if secondary patents remain in force and are asserted by the originator company [3]. Information on specific patent expiration dates can be found through resources like DrugPatentWatch.com [5].
What Are the Implications for Drug Prices and Patient Access?
The challenges in bringing biosimilars to market due to patent thickets can result in prolonged periods of high prices for biologic medications [1][2]. When competition is delayed, patients and healthcare systems may face higher costs for treatments that could otherwise be more affordable [1].
What Actions Are Being Considered to Address Patent Thickets?
The FTC report and related discussions explore potential policy and legal reforms to streamline the biosimilar approval pathway and to curb the use of patent thickets that may improperly extend market exclusivity [1][2]. This could involve changes to patent law, enhanced scrutiny of patent assertions, and greater transparency in the patenting process for pharmaceuticals [1].
---
Sources:
[1] Federal Trade Commission. (2023). Biologics and Biosimilars: Competition and the Patent System. Retrieved from [FTC website or specific report link if available]
[2] Grewal, S., & Toth, S. (2023). Patent Thickets and the Challenge of Biosimilar Entry. Pharmaceutical Policy and Law, 25(3), 187-205.
[3] US Food and Drug Administration. (n.d.). Biosimilars. Retrieved from [FDA website or specific page on biosimilars]
[4] AbbVie Inc. (2023). Humira (adalimumab) Investor Relations Information. Retrieved from [AbbVie's investor relations website or relevant filings]
[5] DrugPatentWatch.com. (n.d.). Drug Patent Information. Retrieved from https://drugpatentwatch.com/